Pharmafile Logo
Pharmafocus logo
Advanced Search

J&J

Showing 15 posts of 219 posts found.

nhs_sign

NHS scraps restriction on availability of J&J’s Imbruvica in leukaemia patients

August 10, 2018
Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, NHS, NICE, UK, imbruvica, leukaemia, pharma

The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), …

News
usmarinetankinbaghdad

Lawsuit alleges pharma giants funded terror in Iraq

August 2, 2018
Business Services, Medical Communications, Sales and Marketing AstraZeneca, Iraq War, J&J, JJ, Litigation, Roche, corruption, terrorism

The United States Justice Department is investigating claims that major pharmaceutical and medical device companies were aware that supplies that …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

July 27, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, China, GSK, Gilead, J&J, JJ, Pfizer, Remicade, Roche, antimicrobial resistance, biosimilar, pharma, pricing, viagra

With the UK in the grip of a record-breaking heatwave, it’s hard to focus on much else over here, but …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week

July 20, 2018
Medical Communications GSK, ICR, J&J, JJ, Novartis, Trump, brexit, top 10

As Brexit negotions have hit a stalemate this week, the United Kingdom’s exit from the European Union has hit the …

News
jj_sign_on_wall

J&J stops Invokana trial early after success in kidney disease and type 2 diabetes

July 17, 2018
Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, invokana, kidney disease, pharma, renal, type 2 diabetesm diabetes

Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy …

News
johnson_and_johnson_jj

J&J ordered to pay $4.68 billion to talc-powder plaintiffs

July 13, 2018
Medical Communications J&J, JJ, Johnson and Johnson, legal, talc powder

A Missouri jury has ordered the New Jersey-based healthcare company Johnson and Johnson to pay $4.69 billion to 22 women …

News

Missouri appeals court overturns $55m J&J verdict

July 6, 2018
Medical Communications, Sales and Marketing Cancer, J&J, JJ, Litigation, appeal, pharma

A $55 million verdict against the multinational pharmaceutical company Johnson & Johnson has been overturned by an appeals court in …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

June 29, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, J&J, JJ, Remicade, Roche, biosimilar Amgen, lung cancer, multiple sclerosis, pharma

Summer seems to be in full swing as we reach the end of June, so it’s time to look back …

News
sandi_peterson

J&J’s second-in-command to retire, alongside executive restructure

June 25, 2018
Medical Communications, Sales and Marketing J&J, JJ, Johnson & Johnson, pharma

Johnson & Johnson’s Group Worldwide Chairman Sandra Peterson (pictured) has announced she is to retire from her role and the …

News
janssen_latest_logo_on_sign_closer

Janssen debuts promising new cancer data at ASCO

June 4, 2018
Research and Development, Sales and Marketing ASCO, Cancer, J&J, JJ, Jassen, erdafitinib, imbruvica, pharma

Janssen took the opportunity at the American Society of Clinical Oncology (ASCO) annual event to present promising new Phase 2 …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

June 1, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Allergan, AstraZeneca, Cancer, Gilead, HIV, J&J, JJ, google, machine learning, melanoma, pharma, top ten

The first day of June – time for another top ten run-down. It’s been a week somewhat characterised by trial …

News
jj

J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex

May 29, 2018
Manufacturing and Production, Research and Development Cancer, Genmab, J&J, JJ, Johnson & Johnson, Roche, darzalex, multiple myeloma, tecentriq

Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

May 11, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, EMA, GSK, J&J, JJ, Novartis, Shire, Takeda, Valeant, biotech, drugs, pharma, pharmaceutical

It’s been a week in which one of the largest pharmaceutical takeovers in history took place and yet it’s not …

News
jj

J&J’s ketamine-based antidepressant showed mixed success at Phase 3

May 8, 2018
Manufacturing and Production, Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Ketamine, antidepressant, depression, esketamine, pharma

Johnson & Johnson has revealed new data on its new depression drug esketamine, its chemically ‘left-handed’ version of the controlled …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

April 20, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, EMA, GW Pharma, J&J, JJ, MHRA, Mylan, Novartis, Sanofi, Shire, Takeda, biotech, drugs, epipen, keytruda, pharma, pharmaceutical

It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023